Filing Details
- Accession Number:
- 0001104659-24-084339
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2024-07-31 16:07:31
- Reporting Period:
- 2024-05-07
- Accepted Time:
- 2024-07-31 16:07:31
- Original Submission Date:
- 2024-05-07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1137883 | Brainstorm Cell Therapeutics Inc. | BCLI | Biological Products, (No Disgnostic Substances) (2836) | 207273918 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1406302 | Chaim Lebovits | C/O Brainstorm Cell Therapeutics Inc. 1325 Avenue Of The Americas 28Th Floor New York NY 10019 | President & Ceo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-05-07 | 66,300 | $0.37 | 1,059,865 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 2,000,847 | Indirect | See footnote |
Footnotes
- On May 7, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'.
- The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.3738 to $0.3747, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
- Includes (i) 1,933,794 shares of Common Stock owned by ACCBT Corp. and (ii) 67,053 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may be deemed the beneficial owner of these shares.